This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 119/24/3125    most recent CIRCULATIONAHA.109.852467v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Jones, A. Articles by Cockerill, G. W. PubMed PubMed Citation Articles by Jones, A. Articles by Cockerill, G. W. Related Collections Animal models of human disease Aneurysm, AVM, hematoma Other Vascular biology Related Article

(Circulation. 2009;119:3125-3132.)
© 2009 American Heart Association, Inc.

Vascular Medicine

Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms

Alun Jones, MBBS^*; Rajdeep Deb, MBBS^*; Evelyn Torsney, PhD; Franklyn Howe, PhD; Mathew Dunkley, MBBS, PhD; Yanosha Gnaneswaran, MRes; David Gaze, PhD; Hosaam Nasr, MBBS; Ian M. Loftus, MD, FRCS; Mathew M. Thompson, MD, FRCS; Gillian W. Cockerill, PhD

From the Department of Cardiovascular Sciences, St George’s University of London, Cranmer Terrace, London, UK.

Correspondence to Dr Gillian Cockerill, Vascular Surgery Research Unit, Cranmer Terrace, Tooting, London, SW17 ORE, UK. E-mail gcockeri{at}sgul.ac.uk

Received May 19, 2007; accepted April 24, 2009.

Background— Development and rupture of aortic aneurysms involve a combination of complex biological processes. Rosiglitazone, a peroxisome proliferator-activated receptor- agonist, has been shown to have a broad spectrum of effects in vivo. The hypothesis that rosiglitazone would reduce aneurysm expansion or rupture was tested in the angiotensin II (Ang II)-induced hypercholesterolemic mouse model.

Methods and Results— Apolipoprotein E-deficient mice, 12 months of age, were allocated to 4 groups. Three groups were infused with Ang II (1 µg · min^–1 · kg^–1), and the fourth was infused with saline. Rosiglitazone was given 1 week before infusion and 1 week after infusion. At day 28, aortic size was measured, and tissues were collected for analyses. Both pretreatment and posttreatment with rosiglitazone inhibited the occurrence of fatal rupture (11 of 30 versus 0 of 30 versus 0 of 15; P=0.0013) and reduced maximal dilatation of the aorta (4.6±0.13 versus 2.4±0.48 versus 2.15±0.46 mm²; P<0.0001). Blood glucose, total cholesterol, body weight, and atherosclerosis did not differ between groups. Pretreatment with rosiglitazone inhibited the Ang II-induced expression of angiotensin type 1a Ang II receptor while having no effect on the angiotensin type 2 Ang II receptor, in addition to reducing Ang II-induced expression of E-selectin, tumor necrosis factor-, and interleukin-6.

Conclusions— Pretreatment or posttreatment with RGZ reduced aortic expansion and rupture in this mouse model. Reduction of lesions in animals pretreated with rosiglitazone is concomitant with decreased expression of inflammatory mediators. Further studies are needed to elucidate the precise mechanism.

---

 

CLINICAL PERSPECTIVE

Related Article:

Circulation: Clinical Summaries
Circulation 2009 119: 3041-3043. [Extract] [Full Text]